短報
Pfizer/BioNtechワクチン接種後のSARS-CoV2抗体の推移
2022 年 96 巻 2 号 p. 56-60
詳細
2022 年 96 巻 2 号 p. 56-60
Objective: We investigated whether there was a difference in the antibody profile after Pfizer/BioNtech vaccination in persons who had already been infected with COVID-19 and those who had not.
Method: Blood samples were obtained before, after the first dose and after the second dose of Pfizer/BioNtech vaccine inoculation in 4 subjects with a history of COVID-19 infection and 62 subjects without a history of COVID-19 infection after obtaining their informed consent. The differences in the antibody titers were examined between those with and without a prior history of COVID-19.
Result: As compared with those without a prior history of COVID-19, those with a prior history of COVID-19 showed significantly higher antibody titers after the first inoculation, and the antibody titers were significantly higher than even those after the second inoculation of subjects without a prior history of COVID-19.
Conclusion: Our findings suggest that a single vaccine dose may be sufficient for subjects with a prior history of COVID-19.
